We serve Chemical Name:3-(2-Methoxyethyl)piperidine CAS:946715-83-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3-(2-Methoxyethyl)piperidine
CAS.NO:946715-83-9
Synonyms:3-(2-Methoxyethyl)piperidine
Molecular Formula:C8H17NO
Molecular Weight:143.22700
HS Code:2933399090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:21.26000
Exact Mass:143.13100
LogP:1.35130
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 3-(2-Methoxyethyl)piperidine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-(2-Methoxyethyl)piperidine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-(2-Methoxyethyl)piperidine Use and application,3-(2-Methoxyethyl)piperidine technical grade,usp/ep/jp grade.
Related News: Wavelength’s growth in the API space comes as nations around the world look to develop redundant supply chains for key generic medicines amid the pandemic. [2-(1-Methyl-1H-pyrazol-5-yl)ethyl]amine manufacturers The Institute for Clinical and Economic Review (ICER) on Friday released its report examining the cost-effectiveness of Soliris, also known as eculizumab, as well as up-and-comer efgartigimod for patients with the myasthenia gravis. 2-Bromo-5-ethynylpyridine suppliers MSD – known as Merck in the US and Canada – is jointly developing Verquvo with Bayer. While MSD hold the commercial rights to the heart failure med in the US, Bayer has the exclusive commercial rights in the rest of the world. tert-butyl N-[2-amino-2-(2-nitrophenyl)ethyl]carbamate vendor & factory Wavelength’s growth in the API space comes as nations around the world look to develop redundant supply chains for key generic medicines amid the pandemic. ,The Institute for Clinical and Economic Review (ICER) on Friday released its report examining the cost-effectiveness of Soliris, also known as eculizumab, as well as up-and-comer efgartigimod for patients with the myasthenia gravis.
